bluuebunny/crossref_metadata_2025_split huggingface dataset:
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high‐dose cytosine arabinoside
Authors: Letendre Louis , Niedringhaus Robert D. , Therneau Terry M. , Gastineau Dennis A. , Goldberg Richard M. , Gerstner James B. , Mailliard James A. , Gundlach William J. , Kardinal Carl G. , Pierre Robert V. 
Published: February 2007

AbstractEffective treatment of the elderly patients (≥ 65 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single‐agent Cytosine Arabinoside (ARA‐C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] 1‐hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients. Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6‐month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.
Treating childhood acute lymphoblastic leukaemia (ALL): Summary of ten years' experience in Italy
Authors: Paolucci G. , Masera G. , Vecchi V. , Marsoni S. , Pession A. , Zurlo M. G. 
Published: February 2007

AbstractBetween 1976 and 1986, 2,093 children with ALL were enrolled in three consecutive generations of trials conducted by the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). A 50% event‐free survival at 5 years was achieved overall in this population, approximately accounting for more than 50% of the entire childhood ALL population in Italy. Participation in the group protocols increased from the original seven founding centers to the current 37 institutions. Results in the standard population (non‐T immunophenotype, non‐FAB L3, and < 50,000 white blood cells [WBC]/ml) were considerably better with more recent, more aggressive protocols. The two major results in this population (N = 540) were a relatively low incidence (8% at 5 years) of central nervous system (CNS) relapse in the “good”‐risk population (< 10,000 WBC, ages 3–6 years, and FAB L1), without the use of cranial irradiation, and a projected 4‐year disease‐free interval for bone‐marrow relapse of 80% in the “average”‐risk group, where a three‐drug reinduction program was adopted after consolidation. Overall, the event‐free survival of the most recent generation (protocol 82, median follow‐up time of 38 months) is 66% at 4 years (95% confidence limits [CL] 61–71). Based on these 10 years of experience, the general strategy of the group for the 90s is outlined and discussed.
Etoposide (VP16) in the treatment of multisystem langerhans cell histiocytosis (histiocytosis X)
Authors: Broadbent V. , Pritchard J. , Yeomans E. 
Published: February 2007

AbstractTen children with Langerhans cell histiocytosis (histiocytosis X) either resistant to or intolerant of corticosteroids received etoposide (VP16). Nine responded. In one instance, partial diabetes insipidus was temporarily reversed. There was no major toxicity. Etoposide should be seriously considered as therapy for patients with LCH in whom the toxicity/benefit ratio of steroid therapy is unacceptably high.
Soft tissue sarcomas in infants younger than 1 year of age: A report of the German soft tissue sarcoma study group (CWS‐81)
Authors: Koscielniak E. , Harms D. , Schmidt D. , Ritter J. , Keim M. , Riehm H. , Treuner J. 
Published: February 2007

AbstractOf 357 patients with soft tissue sarcomas (STSs) who were registered between 1981 and 1986 in the CWS‐81 study, 21 (5.8%) were younger than 1 year of age. Six cases were probably of congenital origin since they were diagnosed in the 1st month of life. There was no difference in clinical grouping (staging and primary site) between infants and older patients. The major histological subsets comprised 12 patients with embryonal rhabdomyosarcoma (57% vs. 44% in older patients) and five patients with fibrosarcoma (23% vs. 2% in older patients). Of 21 patients, 17 received chemotherapy. The response rate (tumor reduction more than 1/3) to exclusive cytostatics therapy within 7–9 weeks, of ten evaluable patients, was 100% (vs. 86% in older patients). Eight of the responders achieved complete remission after 16 weeks of therapy and are in continuous complete remission (CCR). Most patients received 20–50% of the recommended chemotherapy dose for older children, which was calculated using body surface area. No fatal or life‐threatening complications were observed. The eventfree survival rate for children younger than 1 year of age with rhabdomyosarcoma was 70% vs. 47% in older children (no significant difference). Now, 2–5 years after therapy all five fibrosarcoma patients are alive and free of disease.Our data indicate that children under 1 year of age with rhabdomyosarcoma have a slightly better prognosis than older children, when therapy modalities are adapted to age.
Preservation of anaplastic features in Wilms' Tumors after preoperative chemotherapy
Authors: Alvarez‐Silvan Ana M. , Carrasco F. Gavilan , Cuevas G. Pineda , Becerra E. Andrade , Anguita M. L. , Caro A. Martinez , Valles M. C. Gracia , Arcega M. A. Maillo 
Published: February 2007

AbstractIn 4 of 35 childhood Wilms' tumors on record in the Hospital Infantil Virgen de Rocio de Sevilla, it was possible to identify diffuse anaplasia despite the fact these children had received cytoreductive chemotherapy preoperatively.
Leukemic infiltration of the eye: Results of therapy in a retrospective multicentric study
Authors: Lo Curto M. , Zingone A. , Acquaviva A. , Bagnulo S. , Calculli L. , Cristiani L. , Dini G. , Di Tullio M. T. , Guazzelli C. , Jancovic M. , Masera G. , Massolo F. , Nespoli L. , Rosati D. , Russo A. , Werne B. , Zanesco L. 
Published: February 2007

AbstractA multicentric retrospective study on leukemic ophthalmopaty (LO) is reported, including 38 patients (21 males, 17 females) with acute leukemia (AL) observed from 1976 to 1985. LO developed in four patients at the time of diagnosis of AL; ten were in first complete remission (eight off therapy), 12 in second remission, and 12 in combined relapse. The children were treated according to different schedules of systemic and intrathecal chemotherapy with or without radiotherapy (RT) of the affected eye. Ocular remission occurred in 32 of 38 patients, but with subsequent ocular relapse in six of the 32. Complete remission after LO treatment lasting for more than 24, 30, 40, and 78 months was observed in four of the ten children with isolated LO in first AL marrow remission. The authors concluded that systemic and intrathecal chemotherapy probably is associated with RT (at least 30 Gy to the affected eye). Aggressive treatment is justified because children with isolated ocular relapse can still be cured.
Case report of successful use of VP‐16 in nasopharyngeal carcinoma
Authors: Daghistani Doured , Davis Joanna , Toledano Stuart 
Published: February 2007

AbstractWe report the use of VP‐16 as a single agent for the treatment of nasopharyngeal carcinoma. Our patient, a 16‐year‐old Black Haitian male, had complete clinical and radiographic response to VP‐16. The remission continued for 14 months. The patient experienced minimal toxicity. We believe that the good response, excellent compliance, and minimal toxicity experienced by our patient should encourage more trials of VP‐16 as upfront therapy for patients with nasopharyngeal carcinoma.
Testicular relapse in adult acute lymphocytic leukemia: A case report and literature review
Authors: Vukelja Svetislava J. , Swanson S. John , Knight Robert D. , Weiss Raymond B. 
Published: February 2007

AbstractIn the pediatric age group, acute lymphocytic leukemia (ALL) may involve the testicles during complete remission of the disease in the marrow. We report a case of testicular involvement with ALL in an adult and review 11 cases of this phenomenon reported previously, to draw attention to the fact that it can occur at any age. Recognition of this fact is important, because testicular involvement may be the first manifestation of systemic relapse. The treatment of choice is irradiation to both testicles and combination chemotherapy.
Nasopharyngeal Hodgkin's disease with intracranial extension in a child
Authors: Mallouh Ahmad A. 
Published: February 2007

AbstractChildhood Hodgkin's Disease rarely involves the nasopharynx or the brain. This is a report of a 12‐year‐old boy who presented with a 3‐month history of headache, diplopia, dizziness, and early morning vomiting. Computerized axial tomography (CT) scan revealed a nasopharyngeal mass with intracranial extension through the skull base. Biopsy of the nasopharyngeal mass and an upper cervical lymph node was consistent with Hodgkin's disease of mixed cellularity. This, to the author's knowledge, is the first report of a child having the combination of nasopharyngeal and intracranial involvement in Hodgkin's disease.
Patients', parents', and oncologists' perceptions of informed consent for bone marrow transplantation
Authors: Lesko Lynna M. , Dermatis Helen , Penman Doris , Holland Jimmie C. 
Published: February 2007

AbstractBone marrow transplantation (BMT) is gaining increasing acceptance as a therapeutic treatment modality and is being offered to patients even in the early stages of disease in the presence of minimal debilitating symptoms. Despite this, little is known regarding patients' and physicians' perceptions of the process in which informed consent for this controversial and potentially lethal procedure is obtained. Thirty‐nine adult BMT patients and the parents of 61 children undergoing BMT and each of their physicians completed a questionnaire concerning their perceptions of the discussion in which consent for BMT was obtained and their evaluation of the consent document. In addition, the factors influencing patients' and parents' decision to accept BMT and the nature and amount of BMT information retained by patients and parents were assessed. The results indicate that on the whole patients and parents evaluated the BMT consultation and consent document favorably, were motivated by their trust in the physician and their belief in BMT as a cure, retained information regarding major points of informed consent from both the consent document and physician discussion, and had considerable difficulty with recall of the specific toxic side effects associated with BMT. Physicians' perceptions, on the other hand, reflected a less positive view of the extent to which patients and parents were actively involved in the consent process and the readability of the consent document. Perceptions of the informed consent process on the part of oncologist‐investigators and patients which could impede the goals of informed consent and implications for facilitating the process are discussed.
An attempt to use a common staging system in rhabdomyosarcoma: A report of an international workshop initiated by the international society of pediatric oncology (SIOP)
Authors: Rodary C. , Flamant F. , Donaldson S. S. 
Published: February 2007

AbstractOne hundred medical records of children with rhabdomyosarcoma were reviewed independently by ten European and American specialists primarily concerned with pediatric cancer patients. Each specialist assessed the stage of disease using a pre‐treatment staging system (International Society of Pediatric Oncology—Union Internationale Contre le Cancer TNM [SIOP—UICC TNM] and a post‐surgical staging system (Intergroup Rhabdomyosarcoma [IRS] grouping system). These two prognostic systems are based on different criteria, and there is no simple correspondence between them. The reliability of the two systems, based on patients' characteristics extracted from medical records, was similar and satisfactory (Kappa index: 0.78 and 0.82 with the TNM system and with the IRS system, respectively). Nevertheless, the IRS grouping system, which considers a primary method of treatment: Surgery, is dependent upon the surgeon, the institution, and the current concept of treatment. We believe that the TNM system provides the best description of extent of disease and should be used for determining therapeutic options and comparing therapeutic results.
Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
Authors: Pavlidis Nicholas , Nikolaou Nikitas , Tolis Christos , Orfanos Stylianos , Tolis George 
Published: February 2007

AbstractA patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life‐threatening myelosuppression; androgen substitution seemed to reverse bone marrow function and to maintain normal peripheral blood counts.Whether or not androgens are a necessary substitution in hypogonadal patients suffering from cancer and undergoing chemotherapy is discussed.
Adult‐type T‐cell lymphoma in an adolescent with human T‐lymphotropic virus type 1 seropositivity
Authors: Fort John A. , Graham‐Pole John , Mottshaw Gail 
Published: February 2007

AbstractRecently, a form of T‐cell lymphoma associated with seropositivity for human T‐lymphotrop virus type 1 (HTLV‐1) antibody has been described in the adult population. The lymphoma frequently presents with massive hepatosplenomegaly, lymphadenopathy and circulating malignant cells, with a normal bone marrow. HTLV‐1‐associated lymphoma has been seen most frequently inadults from Japan, the Caribbean, and the southeastern United States. We report the first known case of a child with a lymphoma having the clinical and serological features of an HTLV‐1‐associated T‐cell lymphoma.
Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high‐dose methotrexate‐citrovorum rescue
Authors: Hilton Mary A. , Bertolone Salvatore , Patel Chandrakant C. 
Published: February 2007

AbstractThree adolescents and one child with osteosarcoma were studied during multiple courses of high‐dose methotrexate, citrovorum factor rescue (HDMTX‐CFR), with one adolescent treated intermittently over a period of 6 years. Plasma phenylalanine (Phe) and tyrosine (Tyr) were measured immediately before the infusion of MTX and then daily until serum MTX fell below 10−7 M. At 24 hours, all showed marked increases in Phe and in the Phe/Tyr ratio. This suggests inhibition of dihydropteridine reductase (DHPR) which, in association with hepatic Phe hydroxylase, controls plasma concentrations of Phe. Inhibition of this enzyme system is not relieved by CFR. In the adolescent patients, although MTX levels in plasma declined steadily, Phe concentrations, which fell between 24 and 48 hours, rose to a new peak at 4–7 days. Possible reasons for this secondary increase are discussed. The patient with the longest exposure to HDMTX showed an increase in pretreatment Phe/Tyr ratios with time, suggesting damage to liver parenchymal cells not indicated by standard tests of liver function. Evaluation of plasma Phe during the course of HDMTX‐CFR may permit assessment of intracellular concentrations of MTX or its metabolites in the liver without interference by CFR.
Enlargement of mediastinal masses on simulation films: A radiotherapeutic problem in the management of patients with Hodgkin's disease
Authors: Vukelja Svetislava J. , Andejeski Yvonne , Giguere Jeffrey K. , Yuen Albert , Diehl Louis F. 
Published: February 2007

AbstractThe size of the mediastinal mass on standard posterior‐anterior chest radiograph in stage I and stage II Hodgkin's disease has both prognostic and therapeutic importance. But the actual treatment is based on the anterior‐posterior supine simulation film. Problems arise when the prognosis (whether all the disease can be effectively contained in an irradiation port) and toxicity (more lung and heart irradiated or chemotherapy required) are changed when the mass is markedly enlarged on the radiation simulation film. We report two patients with small mediastinal masses on standard posterior‐anterior chest radiographs that appeared to enlarge markedly on radiation simulation films. Differences in the direction of the X‐ray beam, distance from the subject, and patient position are shown to increase artificially the size of a mediastinal mass on simulation films. The staging and therapeutic implications are discussed.
Papillary adenocarcinoma of the renal pelvis in a child: Case report and brief review of the literature
Authors: Moncino Mark D. , Friedman Henry S. , Kurtzberg Joanne , Pizzo Salvatore V. 
Published: February 2007

AbstractTumors of the renal pelvis are not common in adults and are extremely rare in children. Forty‐eight cases of adenocarcinoma of the renal pelvis have been reported, with only one patient under 32 years of age. We report the youngest patient (an 11 year old boy) diagnosed with this tumor and discuss our approach to therapy. We also review the literature with respect to the characteristics and histogenesis of this rare neoplasm.
Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells
Authors: Békássy Albert N. , Liliemark Jan , Garwicz Stanislaw , Wiebe Thomas , Gulliksson Hans , Peterson Curt 
Published: February 2007

AbstractConcentrations of ara‐CTP in leukemic cells isolated from CSF and of ara‐C in lumbar CSF were measured following intraventricular ara‐C administration in two girls with refractory meningeal leukemia. CSF samples were collected with a permanent intrathecal‐lumbar catheter. In contrast to the comparatively short retention of ara‐C in the CSF (t1/2 1.8 to 2.9 hours), there was a high accumulation and an extremely long retention of ara‐CTP in the leukemic cells (t1/2 8.1 to 36 hours). The patients included in this study had an ara‐C‐resistant disease. No obvious relationship was seen between concentrations of ara‐C in the CSF and of ara‐CTP in the leukemic cells. Similar studies were performed after simultaneous intraventricular administration of hydrocortison and ara‐C. Hydrocortison did not increase ara‐CTP retention in the leukemic cells, nor did it effect CSF pleocytosis.
Radiotherapy enhances the toxicity of aminoglutethimide
Authors: Vanek Natalie , Hortobagyi Gabriel N. , Buzdar Aman U. 
Published: February 2007

AbstractWe report a case of radiotherapy‐enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer. This patient was started on aminoglutethimide 6 days prior to radiation therapy, for painful bone metastasis. On day 7 of radiation therapy, she developed an extensive erythematous maculopapular rash over her face, trunk, and extremities. The rash was confluent over the radiation ports, both anteriorly and posteriorly. Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved. Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.
Malignant mesothelioma with bone metastases
Authors: Cheng Wai‐Fung , Berkman Aron W. 
Published: February 2007

AbstractMalignant mesothelioma has rarely been reported to metastasize to bone. This is a report of a 71‐year‐old man who presented with pleural mesothelioma. After a course of chemotherapy, the patient developed lower back pain. Plain X‐ray and bone scan were negative for metastases, but magnetic resonance imaging (MRI) revealed multiple metastatic lesions to the thoracolumbar vertebrae. Subsequent lumbar spine biopsy confirmed the presence of malignant mesothelioma. The patient then received radiation therapy. This report illustrates an unusual presentation for malignant mesothelioma and shows that, in addition, when bone metastases are clinically suspected, MRI may be a useful adjunct to more conventional imaging approach.
Gonadal function after 12‐Gy testicular irradiation in childhood acute lymphoblastic leukaemia
Authors: Castillo L. A. , Craft W. , Kernahan J. , Evans R. G. B. , Aynsley‐Green A. 
Published: February 2007

AbstractGonadal function was assessed in 15 boys with acute lymphoblastic leukaemia (ALL) who had received testicular irradiation. The dose to the testes was 12 Gy in 12, 15 Gy in 1, and 24 Gy in 2 cases. All of those who had received 12 or 15 Gy had normal Leydig cell function, although high levels of gonadotropins suggest subclinical Leydig cell damage. The 2 who had 24 Gy had Leydig cell failure. All who were old enough to produce a semen specimen were azoospermic.
Platinum‐based combination chemotherapy in advanced non‐small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B
Authors: Green Mark R. , Kramar Andrew , Schilsky Richard , Stoopler Marc , Zimmer Bonnie , Ii Frederick Richards , Skarin Arthur , Anderson James R. 
Published: February 2007

AbstractThe Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received prior chemotherapy. Platinum doses were equivalent in the two treatment programs. The total response rate (complete response, partial response, regression of evaluable disease) for the cisplatin‐vinblastine group was 22% (16/73). Failure‐free survival at six months for this group was 41%, survival at six months was 63%. The cisplatin‐ara‐C group had a total response rate of 9% (7/78) with a failure‐free survival at six months of 14% and a six‐month survival of 47%. Severe or life‐threatening toxicity was seen in 73% of cisplatin‐vinblastine cases and 59% of cisplatin‐ara‐C patients. Neither regimen is active enough to warrant designation as “standard therapy” for patients with M1 disease.
Clear cell sarcoma of the kidney: Accuracy of imaging methods for detecting bone metastases. Report from the national Wilms' tumor study
Authors: Feusner James H. , Beckwith J. Bruce , D'Angio Giulio J. 
Published: February 2007

AbstractTo evaluate the accuracy of various imaging methods to screen for bone metastases in patients with clear cell sarcoma of the kidney (CCSK), all such cases reported on the National Wilms' Tumor studies from 1969–1983 were reviewed. Eighty‐two CCSK children were identified, 19 of whom (23%) sustained bone metastases sometime during their course. Thirteen metastatic sites were evaluated by both radiography and bone scanning. In seven instances both modalities were positive; in four the radiograph‐was positive but not the scan; and in only two (15%) was the scan positive in light of a negative radiograph. We recommend both imaging modalities in evaluating children with CCSK in order to detect all metastatic sites in all patients, and to further our observation that “hot” lesions on scintigraphy are more amenable to treatment than “cold” lesions.
Brain tumor as a second malignant neoplasm following neuroblastoma stage IV S
Authors: Ben‐Arush Myriam Weyl , Doron Yaffa , Braun Jacob , Mendelsson Eliane , Dar Hanna , Robinson Eliezer 
Published: February 2007

AbstractA rare brain tumor (spongioblastoma polare) occurring 7 years after treatment of neuroblastoma stage IV S is reported. The literature concerning the occurrence of a second cancer in children exposed to mutagenic therapy for their initial tumor is reviewed, and genetic and environmental factors are discussed. Diminishing aggressiveness of the treatment in childhood cancer with good prognosis should be considered. Continuous follow‐up of children cured of cancer is warranted.